Vera Therapeutics, Inc. Class A Common Stock (VERA) Stock Price

VERAStock
$34.19+53.39%52W
Market Cap$2.46B
P/E
PEG Ratio
Div yield
Beta0.99

VERA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-31.24%
Price vs S&P 500 (4W)4.54%
VGM Score58.01

VERA Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$1.59-$1.52+4.45%(+$0.07)
Q1 2026-$1.37-$1.69-23.00%(-$0.32)
Q4 2025-$1.27-$1.39-9.74%(-$0.12)
Q3 2025-$1.18-$1.26-7.09%(-$0.08)
Q2 2025-$0.62-$1.20-94.77%(-$0.58)

VERA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.25
4.25
4.25
4.25

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
VERAVera Therapeutics, Inc. Class A Common Stock
C$34.19
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Vera Therapeutics, Inc. Class A Common Stock

Vera Therapeutics is a clinical-stage biotech company developing atacicept, a once-weekly subcutaneous fusion protein designed to treat serious autoimmune diseases. The drug works by blocking two key drivers of autoimmune dysfunction—B lymphocyte stimulator and APRIL—which reduces B cell and plasma cell activity and autoantibody production. The company is advancing atacicept through clinical development with a focus on transformative therapeutic potential in immunological disorders.